Moderna
MRNA · NASDAQ · Biotech · United States
Revenue (FY2025)
$1.9B
Net margin
-145.2%
ROE
-32.6%
EPS (FY2025)
-7.26
New to these? P/E, ROE, ROCE and more in Learn.
Ask MarketChacha about MRNA
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Jul 10, 2026
Moderna shares fell sharply after JPMorgan reaffirmed its Sell rating and included the stock on a list of 25 names to short into Q3, citing that recent gains had already priced in pipeline success such as the Merck melanoma partnership.
source 1 ↗· confidence: high - Jul 9, 2026
Moderna shares rose on positive analyst actions including price target increases from Morgan Stanley, BofA, and RBC Capital, alongside news of a new board appointment (Michael McDonnell) disclosed in the July 8 8-K and a recent EU contract for up to 24 million RSV vaccine doses.
- Jul 8, 2026
Moderna shares fell as investors took profits following a sharp June rally that delivered nearly 50% gains, with momentum fading and no major negative catalyst reported.
source 1 ↗· confidence: medium - Jul 2, 2026
Moderna shares rose on positive pipeline updates and encouraging flu vaccine data that lifted sentiment, per multiple July 2 reports; the move continued momentum from recent FDA-related developments.
- Jul 1, 2026
Moderna shares rose on continued momentum from its late-June mRNA pipeline update and positive FDA advisory committee vote on the mRNA-1010 flu vaccine, with no new company-specific catalyst reported for July 1.
- Jun 29, 2026
Moderna shares continued their recent rally on ongoing investor optimism around its cancer pipeline, CAR-T efforts, and plans to expand the mRNA platform beyond vaccines into oncology and other areas, per multiple market reports.
- Jun 26, 2026
Moderna shares surged on optimism from its June 25 Science Day updates highlighting pipeline expansion into oncology and autoimmune diseases, including in vivo CAR-T (mRNA-6007) and T-cell engager programs, plus recent FDA advisory support for its flu vaccine.
- Jun 22, 2026
Moderna shares fell after snapping a six-day rally driven by recent positive FDA flu vaccine updates, amid broader market pressures weighing on biotech stocks and some valuation concerns.
- Jun 18, 2026
Moderna shares rose after an FDA advisory committee voted unanimously 9-0 in favor of its mRNA-1010 (mFlusiva) flu vaccine for older adults, ahead of an August 5, 2026 decision.
Daily moves with the verified reason behind them. Education only — not investment advice.
Financials
Revenue trend
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $1.9B | $-2.8B | -7.26 | -145.2% | -32.6% |
| FY2024 | $3.2B | $-3.6B | -9.28 | -110.0% | -32.7% |
| FY2023 | $6.8B | $-4.7B | -12.33 | -68.8% | -34.0% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q1 | $389.0M | $-1.3B | -3.40 | -345.2% |
| 2025Q3 | $1.0B | $-200.0M | -0.51 | -19.7% |
| 2025Q2 | $142.0M | $-825.0M | -2.13 | -581.0% |
| 2025Q1 | $108.0M | $-971.0M | -2.52 | -899.1% |
| 2024Q3 | $1.9B | $13.0M | 0.03 | 0.7% |
| 2024Q2 | $241.0M | $-1.3B | -3.33 | -530.7% |
| 2024Q1 | $167.0M | $-1.2B | -3.07 | -703.6% |
| 2023Q3 | $1.8B | $-3.6B | -9.53 | -198.3% |
| 2023Q2 | $344.0M | $-1.4B | -3.62 | -401.2% |
| 2023Q1 | $1.9B | $79.0M | 0.19 | 4.2% |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC7/8/2026material
- SEC5/11/2026material
- SEC5/1/2026material
- SEC5/1/2026
- SEC3/5/2026material
- SEC2/20/2026
In the news
- Y Intercept Hong Kong Ltd Sells 444,343 Shares of Moderna, Inc. $MRNAMarketBeat · 7/13/2026
- Moderna (MRNA) Faces A Fresh Valuation Test Following Its Flu Vaccine Decisionsimplywall.st · 7/12/2026
- Stock market today: Dow rises, but Nasdaq falls ahead of SK Hynix stock debut (live coverage)MSN · 7/10/2026
- Moderna (MRNA) Sees Significant Drop in Stock PriceGuruFocus · 7/10/2026
- Moderna Stock Sinks 11%; Its 24 Million-Dose EU Deal Has a No-Minimum CatchTechStock² · 7/10/2026
- Moderna Inc Stock (MRNA) Moved Down by 8.01% on Jul 10: Facts Behind the MovementTradingKey · 7/10/2026
- Moderna (MRNA) Stock May Sit Above Fair Value Following Pipeline ExpansionYahoo Finance · 7/9/2026
- Why Moderna stock is the S&P 500’s big loser todayMSN · 7/9/2026
Education and discussion only — not investment advice. Data from official filings (SEC/BSE), reported company financials, and news — not live exchange quotes. Verify with the linked sources before acting.